Key Highlights

  • ARAY rose 8.50 percent to USD 0.1519 in pre-market trading on November 2, 2026.
  • No company announcement dated late October to November 2, 2026 was identified as the trigger.
  • Fiscal first-quarter 2027 results are due November 4, 2026, with a call at 4:30 p.m. Eastern.
  • Fourth-quarter fiscal 2026 net Revenue was USD 100.9 million, down 21 percent year over year.
  • Order Backlog stood at USD 312.5 million at June 30, 2026, and cash was USD 41.2 million.

A Small Bounce Ahead of Earnings

Accuray (NASDAQ:ARAY) was up 8.50 percent to USD 0.1519 in pre-market trading on November 2, 2026. The implied prior close was about USD 0.14 (calculated), a level consistent with a company release that cited a close of USD 0.137 on October 21, 2026.

No press release, filing or contract announcement dated between late October and November 2, 2026 was identified as the reason for the gain. The more measured read is a rebound in a deeply depressed share price, possibly positioning before the Earnings date.

The Earnings Date on the Calendar

In a company announcement, Accuray said it will report results for the first quarter of fiscal 2027, the quarter ended September 30, 2026, on November 4, 2026. A conference call and webcast are scheduled for 1:30 p.m. Pacific, or 4:30 p.m. Eastern.

That report will be the first update since the fiscal 2026 results. The company has said it is not providing formal revenue or adjusted EBITDA guidance for fiscal 2027, so the reported figures will carry more weight than any forecast.

Business Background and Recent Results

Accuray develops, manufactures and sells radiation therapy systems for cancer treatment, including the CyberKnife and Radixact platforms, along with related services. It is a recognised name in radiation oncology equipment.

In its release dated August 19, 2026, the company reported fiscal 2026 net revenue of USD 401.9 million, down 12 percent, and a net loss of USD 49.2 million. Fourth-quarter net loss was USD 1.9 million, and fourth-quarter adjusted EBITDA was USD 12.9 million. Gross orders for the year were USD 191.9 million, compared with USD 288.0 million a year earlier.

Debt, Liquidity and Penny Stock Risk

The Balance Sheet is the central issue. The company reported about USD 146.4 million of long-term debt, net, against USD 41.2 million of cash and equivalents at June 30, 2026. It also announced a financing transaction with its lender that reduces Leverage and provides covenant relief through December 2027.

A share price near USD 0.15 makes ARAY a penny stock, with sharp volatility, thin extended-hours liquidity and a risk of dilution or listing compliance pressure if the bid price stays low. The sources reviewed did not confirm any specific Nasdaq notice.

What to Watch Next

The November 4, 2026 report should show whether orders and backlog have stabilised after a year of declines. Investors will also watch cash, Debt covenants and any commentary on the financing terms.

Any listing compliance notice, Capital raise or corporate action would be disclosed in a regulatory filing and could shift trading quickly in either direction.